Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer

2018 ◽  
Vol 14 (5) ◽  
pp. e238-e242 ◽  
Author(s):  
Akira Hirano ◽  
Hiroaki Inoue ◽  
Kaoru Ogura ◽  
Akinori Hattori ◽  
Hiroko Yukawa ◽  
...  
2004 ◽  
Vol 36 (Supplement) ◽  
pp. S106???S107
Author(s):  
Timothy Lohman ◽  
Ellen Cussler ◽  
Scott Going ◽  
Rob Blew ◽  
Linda Houtkooper ◽  
...  

2004 ◽  
Vol 36 (Supplement) ◽  
pp. S106-S107
Author(s):  
Timothy Lohman ◽  
Ellen Cussler ◽  
Scott Going ◽  
Rob Blew ◽  
Linda Houtkooper ◽  
...  

2017 ◽  
Vol 13 (5) ◽  
pp. e505-e515 ◽  
Author(s):  
Jamie Stratton ◽  
Xin Hu ◽  
Pamela R. Soulos ◽  
Amy J. Davidoff ◽  
Lajos Pusztai ◽  
...  

Purpose: In postmenopausal women with breast cancer treated with aromatase inhibitors (AIs), most expert panels advise baseline bone mineral density testing with a dual-energy x-ray absorptiometry (DXA) scan repeated every 1 to 2 years. How often this recommendation is followed is unclear. Methods: We performed a retrospective analysis of women with stage I to III breast cancer who started AI therapy from January 1, 2008, to December 31, 2010, with follow-up through December 31, 2012, by using the SEER-Medicare database. Selection criteria included AI use for ≥ 6 months and no recent osteoporosis diagnosis or bisphosphonate use. We used multivariable logistic regression to investigate associations between patient characteristics and receipt of a baseline DXA scan. In patients who continued AI treatment, we assessed rates of follow-up scans. Results: In the sample of 2,409 patients (median age, 74 years), 51.0% received a baseline DXA scan. Demographic characteristics associated with the absence of a baseline DXA scan were older age (85 to 94 years v 67 to 69 years; odds ratio [OR], 0.62; 95% CI, 0.42 to 0.92) and black v white race (OR, 0.68; 95% CI, 0.47 to 0.97). Among patients who underwent a baseline DXA scan and continued AI for 3 years, 28.0% had a repeat DXA scan within 2 years and 65.9% within 3 years. In aggregate, of the 1,164 patients who continued with AI treatment for 3 years, only 34.5% had both a baseline and at least one DXA scan during the 3-year follow-up period. Conclusion: The majority of older Medicare beneficiaries with breast cancer treated with AIs do not undergo appropriate bone mineral density evaluation.


1997 ◽  
Vol 17 (2) ◽  
pp. 118-123 ◽  
Author(s):  
Sameer Huraib ◽  
Hassan Abu-Aisha ◽  
Jamal Abed ◽  
Jamal Al Wakeel ◽  
Mahmoud Al Desouki ◽  
...  

2018 ◽  
Vol 36 (2) ◽  
pp. 105-111 ◽  
Author(s):  
Mohamed Salaheldien Mohamed Alayat ◽  
Ehab Mohamed Abdel-Kafy ◽  
Ali Abdel Monsif Thabet ◽  
Ahmed Salman Abdel-Malek ◽  
Tariq Helmi Ali ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document